Skip to main content

Table 1 Sociodemographic and clinical characteristics of patients by status at end of treatment by univariate Cox proportional-hazards regression (n = 565).

From: Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis

Characteristics

Death during treatment

N (%)

Alive throughout treatment

N (%)

p value

N

37

528

 

Mean age at diagnosis ± SD

45.0 ± 16.2

40.7 ± 13.5

0.03

   Median (Min-Max)

41 (22-88)

38 (18-94)

 

Male Gender

29 (78.4)

423 (80.1)

0.95

Race

American Indian

0

9 (1.7)

0.99

 

African American/Black

13 (35.1)

187 (35.4)

0.97

 

Asian/Pacific Islander

1 (2.7)

10 (1.9)

0.73

 

White

23 (62.2)

322 (61.0)

Ref

Hispanic ethnicity

7 (18.9)

159 (30.1)

0.16

US born

31 (83.8)

364 (68.9)

0.03

HIV positive

24 (64.9)

180 (34.1)

0.02

   HAART during tuberculosis therapy

1/24 (4.2)

27/180 (15.0)

0.10

   History of opportunistic infection

21/24 (87.5)

101/180 (56.1)

0.01

   CD4 count

   

≤ 200 cells/μL1

17/19 (89.5)

108/156 (69.2)

0.14

Median CD4 count at diagnosis (IQR)1

68 (34-104)

105 (47-269)

0.06

Received directly observed therapy2

Yes

28 (75.7)

251 (47.7)

0.02

 

Partial*

4 (10.8)

90 (17.1)

0.67

 

No

5 (13.5)

185 (35.2)

Ref

Episode of inadequate therapeutic regimen

25 (67.6)

161 (30.5)

0.01

During intensive phase3

24 (64.9)

129/525 (24.6)

0.001

Median duration of inadequate treatment (days) (IQR) (n = 153)

23 (6-35)

18 (9-34)

0.18

During continuation phase4

10/33 (30.3)

116/523 (22.2)

0.44

Median duration of inadequate treatment (days) (IQR) (n = 126)

37 (24-50)

29 (13-50)

0.24

   Due to non-adherence

22 (59.5)

142 (26.9)

0.01

During intensive phase3

21 (56.8)

109/525 (20.8)

0.001

Median duration of inadequate treatment (days) (IQR) (n = 130)

8 (5-28)

15 (7-24)

0.13

During continuation phase4

10/33 (30.3)

108/523 (20.7)

0.64

Median duration of inadequate treatment (days) (IQR) (n = 118)

30 (16-50)

29 (14-53)

0.11

   Due to adverse reaction5

10 (27.0)

49/527 (9.3)

0.10

During intensive phase5

7 (18.9)

39/527 (7.4)

0.21

Median duration of inadequate treatment (days) (IQR) (n = 46)

29 (8-39)

14 (6-38)

0.75

During continuation phase5

3 (8.1)

18/527 (3.4)

0.98

Median duration of inadequate treatment (days) (IQR) (n = 21)

25 (1-31)

14 (7-20)

0.40

Hospitalized for tuberculosis6

29 (78.4)

253/526 (48.1)

0.003

Homeless within 1 year of diagnosis7

16/27 (59.3)

138/356 (38.8)

0.04

Substance abuse at diagnosis

23 (62.2)

228 (43.2)

0.13

Sputum smear positive

27 (73.0)

233 (44.1)

0.004

Sputum culture positive

34 (91.9)

471 (89.2)

0.62

Extrapulmonary disease in addition to pulmonary disease

18 (48.7)

143 (27.1)

0.13

Cavitary disease

4 (10.8)

129 (24.4)

0.12

Any prior medical condition

25 (67.6)

288 (54.6)

0.13

  1. 1) Excluding 29 with missing data for CD4 cell count. 2) Excluding 2 with missing data for directly observed therapy. * Partial DOT = DOT used for less than the full duration of treatment (clinicians opted to transition select patients to self-administered therapy (SAT) at the end of the intensive phase of treatment, or initiated DOT in patients previously treated by SAT in whom clinical, radiographic or microbiologic response to treatment was delayed). 3) Excluding 3 with missing data for intensive phase. 4) Excluding 9 with missing data for continuation phase. 5) Excluding 1 with missing data for adverse reaction. 6) Excluding 2 with missing data for hospitalization. 7) Excluding 182 with missing data for housing status.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us